## Loughborough University The Centre for Biological Engineering Doc Ref: FS008.1 : HTA-PR-FORM/007 Acquisition and Receipt of Biological Materials Issue Date:

## ARF No: CBE/ARF/000 75

PART A: To be completed by the Re	eceiver (a separate	form must be c	ompleted for	each sample t	уре)			
A1. Details of Sample/Specimen	·							
Type/ID: (eg primary cell, cell line, tissue, b fluid, excreta, biological agent)	Human Cord	Human Cord Blood (Ficolled) CD34+ isolation				⊠Human □Animal		
Format / Quantity: (eg vials, slides, etc)	3x50mL tube	3x50mL tube containing ~21mL ficol unit. 3 donors total						
Tissue site/Organ source:	Cord Blood							
Batch N°:								
Is the sample/specimen considered If No, go to section A2.		⊠Yes □No						
Is the material obtained from an HTA licenced Tissue Bank with REC approval for generic research use?								
Is the material obtained for storage and use under a project specific NHS REC approval?								
Is the material licensable under the HTA? Indicate source below:						⊠Yes □No		
⊠HTA licensed organisation ⊠Cor	nmercial Supplier	☐ Imported (fro	om outside Eng	gland, Wales o	r N.Ireland)			
If Yes, list lot numbers (or other identifier) & the corresponding assigned unique sample ID	Lot N°: G22122220 G22122220	05953 G22122 05925	2205935,		nique ID (Procuro): 7, S00280718			
If Yes, provide Project Ref N°:	BRA060 & BI	BRA060 & BRA010						
If Yes, provide the name of the PI:	Dr Rob Thomas							
A2. Details of Receipt								
Date/Time of receipt	Date	02/12/2022	02/12/2022		16:00			
ID of Receiver	Name:	Jon Harriman		Dept:	СВЕ			
ID of Supplier/Provider	Name:	Anthony Nolan		Country:	UK			
PART B: To be completed by the R	eceiver							
B1. Inspection and Quarantine								
Has a biological risk assessment for the use of this material been approved?		⊠Yes □No	Ref Number: BRA060 & BRA010					
Physical integrity of the material(s) acceptable?		⊠Yes □No	If No, describe action taken					
Quantity received correct?		⊠Yes □No	If No, describe action taken					
Labelling correct and legible?		⊠Yes □No	If No, describe action taken					
attached to this form?	C of A or equivalen quality			⊠Yes □No □N/A				
	Agreements to ena material eg MTA, S		of ⊠Yes □No □N/A					

to ensure traceability	Details/eviden consent	rtails/evidence/assurance of ⊠Yes □No □N/A nsent				
	Other (describe)		□Yes □No □N/A			
Temporary storage - Quarantine location (as applicable)  Storage Unit I  Within storag  Date/Time of		o unit location ID	into 2x Mixed donor 1mL	OC ULT freezer until 05/12/22 ryo-bank.		
Cubustitus I bus						
Submitted by:	Signature:	1	Date: 05/12/22			
PART C: To be completed by the	departmental Q	uality Manager				
C1. Quality Assurance Checks				,		
Has the sample/specimen been s	□Yes □No □N/A					
Has the donor been screened for	PYes □No □N/A					
Has the sample/specimen been s	□Yes □No □N/A					
Is there evidence that the supplied or other recognised certification?	□Yes □No □N/A					
For HTA licensable material, is th and use of the material under the	☑Yes □No □N/A					
Is there sufficient evidence to sup	sing exemption?	□Yes ☑No □N/A				
C2. Approval for release from qu	arantine					
Can the material be released from released for processing?	□Yes □No					
		☐Accept as is, bu	ut with extra controls			
If No, provide recommendations for deposition of the material and the results of any action relating to non-conforming material.		☐Rework or representation	rocess to meet the ments			
		☐Test to meet sp	pecified requirements			
		☐Return to supp	lier/provider			
		□Disposal				
		Building/Room				
		Storage Unit ID				
If Yes, provide details of storage location (as applicable)		Within storage ur	nit location ID	AS above		
		Database Referen	nce			
		Date/Time of trar	nsfer	Seminar Servicer Laking G		
Approved by:		Signature:	a	Date: 5/(2/22		